Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04654104Unknown

Immune Checkpoints in COPD

Role: collaborator

NCT05509075Unknown

Nutraceuticals and Functional Foods

Role: collaborator

NCT04567212Unknown

Gender Differences and SNPs in Asthmatic Patients

Role: collaborator

NCT03388424Unknown

Quantification of Microbiota in Health and Diseases

Role: collaborator

NCT04385043Phase 2Unknown

Hyperimmune Plasma in Patients With COVID-19 Severe Infection

Role: collaborator

All 5 trials loaded